Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis
Abstract Background Currently, the major treatment modalities of advanced melanoma are immune check point and mitogen-activated protein kinase (MAPK) pathway inhibitors. As lacking head-to-head randomizedcontrolled trials (RCTs) comparing immune check point and MAPK pathway inhibitors, we evaluated...
Main Authors: | Qing An, Zhihao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-5259-8 |
Similar Items
-
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01) -
Updates in Therapy for Advanced Melanoma
by: Bhavana P. Singh, et al.
Published: (2016-01-01) -
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
by: Sandra Huynh, et al.
Published: (2020-06-01) -
Treatment of advanced melanoma - A changing landscape
by: Adriana Hepner, et al. -
Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
by: Bartoušková Marie, et al.
Published: (2020-08-01)